Literature DB >> 28789365

Effects and mechanism of GA-13315 on the proliferation and apoptosis of KB cells in oral cancer.

Shan Shen1, Jingxia Tang1.   

Abstract

The present study describes the effects and mechanism of GA-13315 on the proliferation and apoptosis of KB cells in oral cancer. Oral cancer is twice as common in men than women. More than 90% of oral cancers in men and 85% in women are linked to lifestyle and environmental factors. PPP2R2B methylation may be associated with survival and prognosis in patients with gliomas. In tumor cell proliferation and apoptosis, the mechanism of PPP2R2B remains unclear. In the present study, we found that PPP2R2B expression of H1299 cells is significantly decreased after being treated by GA-13315. KB cells were isolated from patients with oral cancer and treated with GA-13315 (5 µM). Cells without GA-13315 treatment served as the control group. An MTT experiment was performed to detect the post-treatment cell growth between the groups. A flow cytometry was used to detect cell apoptosis. Western blot analysis and quantitative polymerase chain reaction methods were used for detecting the expression of PPP2R2B. Compared with the control group, the cell proliferation of the treatment group slowed after being treated with GA-13315. The difference was statistically significant (P<0.05). Western blotting showed that the PPP2R2B expression of cells was reduced after being treated with GA-13315. Compared with the control group, the difference was statistically significant (P<0.05). According to results from the Transwell migration assay, the invasiveness of the KB cells of oral cancer were weakened after being treated by GA-13315. GA-13315 can accelerate the apoptosis of oral cancer cells and presents a dose correlation. The biological effect is exerted through the decrease of PPP2R2B.

Entities:  

Keywords:  PPP2R2B; apoptosis; oral cancer

Year:  2017        PMID: 28789365      PMCID: PMC5529787          DOI: 10.3892/ol.2017.6279

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Oral cancer is the generic term for a malignant tumor of the oral cavity. Most of these types of cancers are considered squamous cell carcinomas, i.e., mucosal variations (1). Oral cancer generally includes gingival and tongue cancer, and is commonly seen in the head and neck (2). Most types of oral cancer are related to unhealthy living habits, such as the oral use of tobacco and betel leaf. Since the space of the oral cavity is small but the blood supply is rich, with more lymph distribution, oral cancer is easily transferred at an early stage. This may cause certain challenges regarding treatment (3,4). In the past, synthetic gibberellin was widely used as the conditioning agent for plant growth (5). Synthetics of α,β-unsaturated ketone unit with gibberellin revealed the antitumor activity of the gibberellin ramification (6). GA-13315 is a chemical compound that includes α,β-unsaturated ketone (Fig. 1). Some research shows that GA-133315 has antitumor properties in rats with xenotransplantation of tumor cells for non-small cell lung cancer (A549 cells), but the antitumor effect of GA-13315 has not been determined yet (7). More recent research shows that GA-13315 offers good treatment for breast cancer in patients with multidrug-resistant, which is exerted through the expression of P-glycoprotein (ABCB1). In order to investigate the effect on oral cancer, we studied the effect mechanism through the use of cancer cell line H1299 in this study.
Figure 1.

GA-133315 chemical structure.

Materials and methods

For the preparation of the cell suspension with high activity, the KB cell concentration was adjusted to 5×106-1×107/ml by 10% FCS RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA). A 5–50 µl glass tube was prepared to contain a 40 µl cell suspension after centrifugation at 1,050 × g for 5 min. A scrubbing solution (Keygen, Nanjing, China) was used to wash the 4°C inactivated rabbit serum twice for 30 min, at which time a 2 ml scrubbing solution was added. The centrifugal parameter was set as 850 × g for 5 min; wash at 4°C of 50 µl rabbit anti-rat fluorescent marker (Biosharp, Hefei, China) for 30 min; fixing after washing twice; the film was observed under a light microscope (Labconco, Kansas City, MO, USA).

Detection of MMT cell activity

An MTT experiment was used to detect cell activity. The suspension of 160 µl with 8×103/µl cells were inoculated into a 96-well plate for cell contact overnight. In order to detect the cell toxicity of GA-13315, GA-13315 (Sigma-Aldrich, San Francisco, CA, USA) was added to the cell culture medium with the total amount of 200 µl. Cells were cultured for 48 h in a medium with GA-13315, then washed and placed in the RIPA lysis buffer (Beyotime, Shanghai, China) with 1 mM PMSF, 1 µg/ml trasylol and 0.5 µg/ml eupeptin for pyrolysis on ice. An equivalent cell lysis solution (20 µg proteins; Beyotime) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transfected to the polyvinylidene fluoride film (KeyGen). TBST (10 mM Tris-HCl, 150 mM NaCl, and 0.1% Tween-20, pH 8.0) was sealed for 1 h under room temperature using 5% skim milk. After being incubated overnight using rabbit polyclonal PPP2R2B antibody (dilution, 1:200; cat. no. ab137609) under 4°C, it was washed and hatched for 2 h at 25 °C using secondary goat anti-rabbit (HRP) IgG antibody (dilution, 1:2,000; cat. no. ab6721) (both from Abcam, Cambridge, MA, USA). It was visually tested by enhanced western blotting and phototope™-HRP visual kits (Cell Signaling Technology, Danvers, MA, USA). FluorChem E system (ProteinSimple, San Jose, CA, USA) was used to analyze imaging. ImageJ sofware (version X; Media Cybernetics, Silver Springs, MD, USA) was used for quantization of protein relative expression by referring to β-actin. Cells were seeded overnight in a 6-well plate (Corning Inc., Corning, NY, USA) based on the density of 1×105 cells/plate. GA13315 with different doses was used for simulation, while 0.1% DMSO was used for control. It was continuously cultured for 48 h under 37°C. TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) was used for cellular total RNA extraction. Then, 1 µg of total RNA was used for cDNA first strand synthesis. M-MLV First Strand kits were used for synthesis. ABI PRISM® 7500 Real-Time PCR system and SYBR® Premix Select Master Mix kit (Thermo Fisher Scientific) were used for amplification of the genes of interest. β-actin was used as an internal reference. Specific primers were as follows: β-actin forward, 5′-CACCTTCTACAATGAGCTGCGTGTG-3′ and reverse, 5′-ATAGCACAGCCTGGATAGCAACGTAC-3′; forward, 5′-AGTAGTAGTAGTTGTGAGTGTGT-3′ and reverse, 5′-AAACAACCACAACAAAATAATACC-3′. The thermal cycle program was as follows: At 50°C for 2 min, at 95°C for 2 min, at 95°C for 15 sec, 45 cycles, at 55°C for 30 sec, at 72°C for 1 min. Specific melting curves were adopted to describe each reaction. The mean value of mRNA expression was calculated for the genes of interest in each group. ΔCq = Cqtarget gene - Cqβ-actin; -ΔΔCq = -(ΔCqMCF-7/adr-ΔCqMCF-7). A millipore filtration culture chamber or double-chamber co-culture system (Corning Inc.) was used with a cell culture density of 1×106. The experimental procedures were conducted on built-in standard specifications.

Statistical analysis

SPSS 20.0 statistical analysis software (IBM SPSS, Armonk, NY, USA) was used to analyze collected data. All measurement data are presented as mean ± standard deviation. SPSS 17.0 (SPSS, Inc., Chicago, IL, USA) software was used for processing. Repeatedly measured data via the ANOVA method was adopted for statistical treatment. The t-test of two independent samples was used for measurement data between groups, and the paired t-test was used for intra-group comparison. The χ2 test was used for enumeration data. P<0.05 was considered to indicate a statistically significant difference.

Results

KB cell viability was tested by MMT in the treatment group. It was found that the cell viability significantly decreased after being treated by GA-13315 for 48 h. The difference was statistically significant (P<0.05) as compared to the control group (Fig. 2).
Figure 2.

MTT study results: The cell viability significantly decreased after being treated by GA-13315. The difference was statistically significant (P<0.05) as compared to the control group.

Decreased KB apoptosis after treatment with GA13315

Flow cytometry was used to test cell apoptosis between the two groups. The results showed that KB apoptosis significantly increased after being treated by GA13315. The difference was statistically significant (P<0.05) as compared to the control group (Fig. 3).
Figure 3.

(A) Apoptosis significantly increases after treatment with GA-13315. (B) Apoptosis significantly increased in the treatment group as compared to the control group. The difference was statistically significant (P<0.05) as compared to the control group.

GA-13315 promotes H1299 apoptosis via downregulating PPP2R2B

Western blotting and quantitative polymerase chain reaction (qPCR) tests found that PPP2R2B expression among cells in the treatment group was significantly lower than that of the control group (Fig. 4). The difference was statistically significant (P<0.05).
Figure 4.

(A) Results of western blot analysis show that PPP2R2B expression in the treatment group was significantly lower, (B) than that of the control group. The difference was statistically significant (**P<0.05). Additionally, qPCR results (C) showed that PPP2R2B expression was relatively lower in the treatment group. The difference was statistically significant (**P<0.05). qPCR, quantitative polymerase chain reaction.

GA13315 lowers the cell invasion ability

After cell invasion was tested by Transwell migration assay between the two groups, the results showed that KB cell invasion ability was significantly decreased after treatment with GA-13315. The difference was statistically significant (P<0.05) as compared to the control group (Fig. 5).
Figure 5.

KB cell invasion ability significantly decreased after treament with GA-13315. The difference was statistically significant (**P<0.05) as compared to the control group.

Discussion

Oral cancer is a malignant tumor commonly seen in the head and neck region, which is ranked with oropharyngeal cancer in the top six of systematic malignant tumors. In some high-prevalence areas, new cases account for 25% of male malignant tumors every year (1). Treatments for patients with oral cancer often cause dysfunction of important organs, leading to unclear speaking, dysphagia and eating disorders, as well as changes in facial appearance and impacts on quality of life. Although oral cancer is not listed in the top 10 of malignant tumors, its morbidity and mortality cannot be ignored. According to global statistics in 2008, new oral cancer cases were approximately 274,000 and annual cases of death were 127,000, 2/3 of which were reported in 40–60-year-old adults. Also, 2/3 of the cases were in developing countries. It should be noted that oral cancer itself and its treatment course usually cause functional injuries to vital organs and facial feature damage, thereby seriously affecting patients' social communications (8–10). GA-13315 is a chemical compound containing α,β-unsaturated ketone. In previous research of A549 tumor cells, GA-13315 reduced the expression of blood coagulation factor VIII, microvessel density and vascular endothelial growth factors. This indicates that it plays a role in anti-angiogenesis. These results show that GA-13315 has activities of anti-angiogenesis that contribute to the development of anticancer characteristics (11,12). Therefore, we believe that GA-13315 has certain antitumor effects. The PPP2R2B gene belongs to phosphatase II regulation subunit B. Protein phosphatase 2 is one of four major types of serine/threonine phosphatases, and it plays important roles in cell growth and division (13). It consists of a common heterogeneous core enzyme, a catalyst subunit and a constant adjusting subunit. Various kinds of adjusting subunits play their own roles (14). Some research has found that the genetic defect in the 5′UTR region may lead to rare type 12 autosomal dominant spinocerebellar ataxias (15). Moreover, PPP2R2B methylation may be associated with survival and prognosis in patients with gliomas (16). In tumor cell proliferation and apoptosis, the mechanism of PPP2R2B remains unclear. In the present study, we found that PPP2R2B expression of H1299 cells is significantly decreased after being treated by GA-13315. The difference is statistically significant (P<0.05) as compared to the control group. We believe that GA-13315 may increase apoptosis in oral cancer cells via regulating PPP2R2B and does show a correlation to dosage. This biological effect is completed via downregulating PPP2R2B.
  15 in total

Review 1.  Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2010-04-18       Impact factor: 5.337

2.  Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1.

Authors:  Jiao Mo; Min Kang; Jun-Xian Ye; Jing-Bo Chen; Hong-Bin Zhang; Chen Qing
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-09       Impact factor: 3.333

Review 3.  Diversity, regulation, and evolution of the gibberellin biosynthetic pathway in fungi compared to plants and bacteria.

Authors:  Christiane Bömke; Bettina Tudzynski
Journal:  Phytochemistry       Date:  2009-06-25       Impact factor: 4.072

4.  Bioimpedance for Oral Cancer Detection in Clinical Practice and its Applicability in Developing Nations.

Authors:  Manas Bajpai; Manika Arora; Betina Chandolia
Journal:  J Coll Physicians Surg Pak       Date:  2016-08       Impact factor: 0.711

5.  Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12.

Authors:  S E Holmes; E E O'Hearn; M G McInnis; D A Gorelick-Feldman; J J Kleiderlein; C Callahan; N G Kwak; R G Ingersoll-Ashworth; M Sherr; A J Sumner; A H Sharp; U Ananth; W K Seltzer; M A Boss; A M Vieria-Saecker; J T Epplen; O Riess; C A Ross; R L Margolis
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

Review 6.  Lifestyle risk factors for oral cancer.

Authors:  Stefano Petti
Journal:  Oral Oncol       Date:  2008-07-31       Impact factor: 5.337

Review 7.  Socioeconomic inequalities and oral cancer risk: a systematic review and meta-analysis of case-control studies.

Authors:  David I Conway; Mark Petticrew; Helen Marlborough; Julien Berthiller; Mia Hashibe; Lorna M D Macpherson
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

8.  Mobile Phone Imaging in Low Resource Settings for Early Detection of Oral Cancer and Concordance with Clinical Oral Examination.

Authors:  Nabihah Haron; Rosnah Binti Zain; Wan Maria Nabillah; Amyza Saleh; Thomas George Kallarakkal; Anand Ramanathan; Suraya Hani Mohd Sinon; Ishak Abdul Razak; Sok Ching Cheong
Journal:  Telemed J E Health       Date:  2016-08-19       Impact factor: 3.536

9.  Identification of salivary metabolomic biomarkers for oral cancer screening.

Authors:  Shigeo Ishikawa; Masahiro Sugimoto; Kenichiro Kitabatake; Ayako Sugano; Marina Nakamura; Miku Kaneko; Sana Ota; Kana Hiwatari; Ayame Enomoto; Tomoyoshi Soga; Masaru Tomita; Mitsuyoshi Iino
Journal:  Sci Rep       Date:  2016-08-19       Impact factor: 4.379

10.  Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.

Authors:  Aleksandra Majchrzak-Celińska; Marta Słocińska; Anna-Maria Barciszewska; Stanisław Nowak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2015-09-04       Impact factor: 3.240

View more
  1 in total

1.  Anti-tumor effects and mechanism of GA-13315, a novel gibberellin derivative, in human lung adenocarcinoma: an in vitro and in vivo study.

Authors:  Lin Xie; Yajuan Chen; Jingbo Chen; Hongbin Zhang; Yedan Liao; Yonghong Zhou; Ling Zhou; Chen Qing
Journal:  Cell Mol Biol Lett       Date:  2019-01-10       Impact factor: 5.787

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.